R 343
Alternative Names: R-343; R-940343Latest Information Update: 27 Aug 2013
At a glance
- Originator Rigel Pharmaceuticals
- Class Antiallergics; Antiasthmatics; Diamines; Pyrimidines; Small molecules
- Mechanism of Action Immunoglobulin inhibitors; Syk kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Allergic asthma
Most Recent Events
- 26 Aug 2013 Discontinued - Phase-II for Allergic asthma in Canada (Inhalation)
- 26 Aug 2013 Discontinued - Phase-II for Allergic asthma in USA (Inhalation)
- 01 Jul 2013 Rigel Pharmaceuticals completes the phase II SITAR trial in Allergic asthma in USA and Canada (NCT01591044)